LH

ACCE-researched
Labcorp Holdings Inc. Common Stock
Healthcare · Diagnostics & Research · NYSE · United States
$320.71-0.63%
Market cap $26.0BNext earnings 2026-10-27Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$320.71+0.0%
confidence-weighted across 4 of 6 models
Now $320.71
$320.71
$157.66$432.70
TrimSilver71
Price vs fair value
26.1% above
-20.7% to fair value
ACCE score
66
out of 100
Analysts
80% buy
20 covering
P/E
26.5x
forward 16.6x
1-year return
+15.7%
Dividend yield
0.89%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • moderate
    Insider selling only
    Last 10 disclosed transactions show $0 buys vs $2.16M in sales, signaling no insider conviction at current price levels.
  • moderate
    Thin net margin
    Net margin of 6.7% is low for diagnostics; leaves limited buffer if revenue growth decelerates or costs rise.
Reports in 36 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+15.0% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish80% buy · 20 covering analysts
● Strong buy 13● Buy 3● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 67% of peers
low 0.0x26.5xhigh 44.6x
ROEbetter than 17% of peers
low -4584%12%high 162%
Div yieldbetter than 83% of peers
low 0.0%0.9%high 1.3%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
DGXQuest Diagnostics Incorporated Common Stock$27.2B26.214.6%0.821.3%-Compare
MTDMettler-Toledo International Inc. Common Stock$27.9B31.329.5%-91.050.0%-Compare
GHGuardant Health Inc. Common Stock$24.1B--4584.5%-15.420.0%-Compare
ILMNIllumina Inc. Common Stock$36.2B44.632.3%0.730.0%-Compare
MEDPMedpace Holdings Inc. Common Stock$17.1B36.0162.2%0.050.0%-Compare
IDXXIDEXX Laboratories Inc. Common Stock$40.3B36.074.2%0.530.0%-Compare

Sector report card

Where LH ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 36 days, last quarter beat by 0.0%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+2.9%
1 month
-2.9%
3 months
+25.4%
6 months
+21.9%
YTD
+27.8%
1 year
+15.7%

SEC filings

40 filings
September 2026
Sep 10
8-KCurrent reportPeriod 2026-09-10
Sep 3
Form 4Insider transactionPeriod 2026-09-01
Sep 3
Form 4Insider transactionPeriod 2026-09-01
37 more filings + AI summaries on Investor+.INVESTOR